EC Approves Amgen's BLINCYTO for Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
November 24, 2015 at 04:20 AM EST
Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted conditional marketing authorization for BLINCYTO® ...